Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29653592 | 1.00 | CYP1A2 (0.67) | CYP1A2CYP2D6NAPRTRECQLTBXAS1 | |
| SCHEMBL10655526 | 0.92 | CYP1A2 (0.61) | CYP1A2CYP2D6NAPRTRECQLTBXAS1 | |
| SCHEMBL8641267 | 0.87 | CYP1A2 (0.62) | CYP1A2CYP2D6NAPRTRECQLTBXAS1 | |
| SCHEMBL3398316 | 0.86 | CYP1A2 (0.67) | CYP1A2CYP2D6NAPRTRECQLCHRM2 | |
| SCHEMBL14189533 | 0.85 | CYP1A2 (0.65) | CYP1A2CYP2D6RECQLCHRM2CYP3A4 | |
| SCHEMBL1815219 | 0.85 | RECQL (0.66) | CYP1A2CYP2D6NAPRTRECQLCHRM2 | |
| SCHEMBL29644833 | 0.85 | RECQL (0.66) | CYP1A2CYP2D6NAPRTRECQLCHRM2 | |
| SCHEMBL3722631 | 0.84 | CHRM2 (0.67) | CYP1A2CYP2D6NAPRTRECQLTBXAS1 | |
| SCHEMBL25179537 | 0.83 | TBXAS1 (0.62) | CYP1A2CYP2D6NAPRTTBXAS1CYP3A4 | |
| SCHEMBL423358 | 0.83 | CYP1A2 (0.62) | CYP1A2CYP2D6NAPRTRECQLCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115873839-B | Detection material for detecting titer of MOG antibody and preparation method thereof | 成都海默云因医学检验实验室有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115873839-A | Detection material for detecting MOG antibody titer and preparation method thereof | 成都海默云因医学检验实验室有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-121570485-A | Application of GBP6 target in reversing cholangiocarcinoma cell gemcitabine resistance | 浙江省肿瘤医院 | 2026-02-27 | — | — | CN | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| CN-119300805-A | Skin care compositions and methods of use | 高露洁-棕榄公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119110720-A | Cosmetic composition | 布茨公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-119072299-A | Cosmetic composition containing retinoid, centella asiatica extract and dipeptide | 布茨公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118984696-A | Kit of cosmetic composition | 布茨公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-118973547-A | Skin care composition comprising vitamin E and vitamin B3 | 高露洁-棕榄公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118973546-A | Skin care composition comprising vitamin E and vitamin B3 | 高露洁-棕榄公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | disclosed |
| US-4728594-A | PHOTORESISTS FOR MAKING SEMICONDUCTORS | HITACHI CHEMICAL CO., LTD. (JP) | 1988-03-01 | — | — | US | disclosed |
| US-4690921-A | BACTERICIDES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1987-09-01 | — | — | US | disclosed |
| US-4608373-A | BACTERICIDES, ANTIBIOTICS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-08-26 | — | — | US | disclosed |
| EP-0189271-A2 | Photosensitive composition | Hitachi Chemical Co., Ltd. (JP) | 1986-07-30 | — | — | EP | disclosed |
| EP-0061768-B1 | N-AMIDO SUBSTITUTED DIPEPTIDES | USV PHARMACEUTICAL CORPORATION (US) | 1986-05-14 | — | — | EP | disclosed |
| EP-0142274-A2 | Cephalosporin compounds and salts thereof, their production, and medicaments containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1985-05-22 | — | — | EP | disclosed |
| EP-0112164-A2 | Cephem compounds, and their production, and medicaments containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1984-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CYP1A2 4845/4885CYP2D6 4576/4885NAPRT 3787/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | CYP1A2 4845/4885CYP2D6 4576/4885NAPRT 3787/4885 |
| US-20090048223-A1 | Sulfonamide compound | ALK, AKT1, ARAF | CYP1A2 1718/4885CYP2D6 2886/4885NAPRT 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.